Personalized Adaptive Immune Modulation for Melanoma Treatment

A next-generation melanoma treatment system that integrates inflammasome inhibition, neoantigen profiling, and microRNA-based immunomodulation to achieve personalized, real-time adaptive immune response modulation.

The original patent's method of treating melanoma with dapansutrile has limitations in terms of efficacy and patient response variability. The new inventive concept addresses these limitations by incorporating advanced technologies to create a personalized, adaptive treatment approach that can effectively modulate the immune response to melanoma.

The inventive concept comprises a dapansutrile-based inflammasome inhibitor module, a personalized neoantigen profiling module, and a microRNA-based immunomodulation module. These modules interact to adaptively modulate the immune response to melanoma in real-time, ensuring a more effective and targeted treatment. The system can be integrated with machine learning-based algorithms, nano-particle based biosensors, and CRISPR-Cas9 systems for targeted gene editing, to further enhance its capabilities.

The new claims introduce a paradigm shift in melanoma treatment by integrating multiple advanced technologies to achieve personalized, adaptive immune response modulation. The inventive concept's novelty lies in its ability to adaptively modulate the immune response in real-time, which is not possible with the original patent's method.

Alternative embodiments of the inventive concept could include the use of different inflammasome inhibitors, varying neoantigen profiling techniques, or alternative microRNA-based immunomodulation approaches. The system could also be integrated with other treatment modalities, such as chemotherapy or radiation therapy, to create a comprehensive treatment strategy.

The inventive concept has significant commercial potential in the melanoma treatment market, which is expected to grow substantially in the coming years. The system's ability to provide personalized, adaptive treatment could lead to improved treatment outcomes and increased patient satisfaction, making it an attractive option for pharmaceutical companies, healthcare providers, and patients.